PART 01: Executive summary • Highlights PART 02: Scope of the report • Market Overview • Assumptions • Top-vendor offerings PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights PART 05: Allergies: Overview • Prevalence of allergic diseases PART 06: Pipeline analysis PART 07: Market landscape • Market overview • Five forces analysis PART 08: Market segmentation by product type • Global SCIT market • Global SLITD market • Global SLITT market PART 09: Geographical segmentation • Allergy immunotherapies market in Europe • Allergy immunotherapies market in Germany • Allergy immunotherapies market in France • Allergy immunotherapies market in North America • Allergy immunotherapies market in US • Allergy immunotherapies market in ROW PART 10: Market drivers • Presence of high unmet medical needs • Existence of novel molecules in pipeline • Increasing prevalence of allergic rhinitis and asthma coupled with high consumption of tobacco • Upsurge of allergies due to increase in environmental pollution PART 11: Impact of drivers PART 12: Market challenges • Increased preference for CAM • Poor patient adherence and high dropout rates • High cost of allergic immunotherapy PART 13: Impact of drivers and challenges PART 14: Market trends • Emergence of SLITT • Advent of SPIRE • Strategic alliances for novel drug developments • Identification of new allergen targets PART 15: Vendor landscape • Competitive scenario • ALK-Abello • Stallergenes • Merck Group • Allergy Therapeutics • Other prominent vendors PART 16: Appendix • List of abbreviations PART 17: Explore Technavio List of Exhibits Exhibit 01: Product offerings Exhibit 02: Impact of key customer segments 2015 Exhibit 03: Prevalence of HDM allergies in major countries 2015 Exhibit 04: Incidence of allergies 1920-2020 (% of population) Exhibit 05: Prevalence of allergies in US 2015 Exhibit 06: Prevalence of allergies in Europe 2015 Exhibit 07: Global allergy immunotherapies market: Pipeline portfolio Exhibit 08: Global allergy immunotherapies market according to drug phase 2015 Exhibit 09: Major pipeline events for allergy immunotherapies 2016-2017 Exhibit 10: Global allergy immunotherapies market snapshot: Developed and emerging markets 2015 Exhibit 11: Growth opportunities for global allergy immunotherapies market Exhibit 12: Global allergy immunotherapies market 2015-2020 ($ billions) Exhibit 13: Comparison of active ingredients used in allergy immunotherapy Exhibit 14: Major healthcare reforms in global allergy immunotherapies market Exhibit 15: Five forces analysis Exhibit 16: Global allergy immunotherapy market segmentation by product type 2015 Exhibit 17: Advantages of short-course SCITs Exhibit 18: Opportunity analysis of global SCIT market Exhibit 19: Global SCIT market 2015-2020 ($ millions) Exhibit 20: Opportunity analysis of global SLITD market Exhibit 21: Global SLITD market 2015-2020 ($ millions) Exhibit 22: Opportunity analysis of global SLITT market Exhibit 23: Global SLITT market 2015-2020 ($ millions) Exhibit 24: Comparison between whole allergen immunotherapies, SCIT, and SLIT Exhibit 25: Global allergy immunotherapies market segmentation by product type 2015-2020 ($ millions) Exhibit 26: Global allergy immunotherapies market segmentation by product type 2015-2020 Exhibit 27: Global allergy immunotherapies market: YoY revenue and growth based on product type 2015-2020 ($ millions) Exhibit 28: Global allergy immunotherapies market: Geography outlook (2015-2020) Exhibit 29: Revenue and growth outlook in different countries 2015 Exhibit 30: Global allergy immunotherapies market by geographical segmentation 2015 Exhibit 31: Allergy immunotherapies market in Europe 2015-2020 ($ millions) Exhibit 32: Market share of SLITT and SCIT/SLITD in Europe 2015 Exhibit 33: Market share of allergy immunotherapies in Europe Exhibit 34: Allergy immunotherapies market in Germany 2015-2020 ($ millions) Exhibit 35: Allergy immunotherapies market in France 2015-2020 ($ millions) Exhibit 36: Allergy immunotherapies market in North America 2015-2020 ($ millions) Exhibit 37: Market share of SLITT and SCIT/SLITD in North America 2015 Exhibit 38: Allery immunotherapies market in North America Exhibit 39: Market share of allergy immunotherapies in North Americas Exhibit 40: Allergy immunotherapies market in US 2015-2020 ($ millions) Exhibit 41: Allergy immunotherapies market in ROW 2015-2020 ($ millions) Exhibit 42: Global allergy immunotherapies market revenue by geography 2015-2020 ($ millions) Exhibit 43: Global allergy immunotherapies market revenue by geography 2015-2020 Exhibit 44: Global allergy immunotherapies market: YoY revenue and growth based on geography 2015-2020 ($ millions) Exhibit 45: Unmet medical needs for severely affected individuals: Key allergens and severe allergic cases Exhibit 46: Impact of drivers Exhibit 47: Use of CAM therapies among individuals in US Exhibit 48: Comparison of different cost components of allergy immunotherapy ($) 2014 Exhibit 49: Impact of drivers and challenges Exhibit 50: Advantages of SPIRE allergy therapies Exhibit 51: Market share analysis Exhibit 52: Market position of top vendors 2015 Exhibit 53: Competitive position of vendors Exhibit 54: Key vendors: Geographical presence 2015 Exhibit 55: Market share analysis in US Exhibit 56: Market share analysis in Europe Exhibit 57: Business segmentation by revenue 2015 Exhibit 58: ALK-Abello: YoY revenue and growth rate of SCIT/SLIT drops 2013-2015 ($ millions) Exhibit 59: Geographic segmentation of SCIT/SLIT drops 2015 Exhibit 60: ALK-Abello: YoY revenue and growth rate of SLIT tablets 2013-2015 ($ millions) Exhibit 61: ALK-Abello: Geographic segmentation of SLIT tablets 2015 Exhibit 62: ALK-Abello: Metrics analysis Exhibit 63: Product categories by revenue Exhibit 64: Stallergenes: Geographical segmentation by revenue 2015 Exhibit 65: Stallergenes: Metrics analysis Exhibit 66: Allergopharma: YoY revenue and growth rate of allergy immunotherapy products 2013-2015 ($ millions) Exhibit 67: Merck Group: Metrics analysis Exhibit 68: Allergy Therapeutics: YoY revenue and growth rate of key allergy immunotherapies 2013-2015 ($ millions) Exhibit 69: Allergy Therapeutics: Products by revenue 2015 Exhibit 70: Allergy Therapeutics: Geographical segmentation by revenue 2015 Exhibit 71: Allergy Therapeutics: Metrics analysis

ALK-Abello, Stallergenes, Merck Group, Allergy Therapeutics, Adamis Pharmaceuticals, Aimmune Therapeutics, Anergis, ASIT biotech, Biomay, Circassia, DBV Technologies, Genentech, HAL Allergy, Laboratorios LETI, Mitsubishi Tanabe Pharma, Nycomed, Sementis, Shionogi, Torii, Tunitas Therapeutics, VentiRx Pharmaceuticals, Verona Pharma.